OmniActive Health Technologies launched Fenavari on July 27, 2026, a proprietary botanical ingredient built from standardised fenugreek and shatavari extracts and aimed at menopause support. The company, which lists Bridgewater, New Jersey and Mumbai, India, is selling the blend to manufacturers, not consumers, and PR Newswire called it a "clinically backed, integrated extract" for women through perimenopause, menopause and post-menopause.
That clinical framing matters because perimenopause is rarely one-note. Hot flushes, sleep disruption, mood changes, irritability, fatigue and broader quality-of-life complaints all tend to travel together, which is why ingredient suppliers now like a multi-symptom story. OmniActive says Fenavari was tested in a randomised, double-blind, parallel, placebo-controlled study, and a 2026 study listing says both doses significantly reduced hot flashes and night sweats by Day 84, with significant improvements also seen in anxiety. Shatavari is already being studied on its own too: ClinicalTrials.gov lists NCT07441109, Shatavari Root Extract for Perimenopausal Symptoms, published on March 3, 2026, and PubMed Central carries a paper on the efficacy and safety of shatavari root extract in perimenopause.
Standardisation is the bit that usually gets buried under botanical romance. In supplements, standardised extracts are meant to signal consistency, quality control and reproducibility, which is exactly what brands want in a crowded menopause aisle where vague wellness claims are increasingly threadbare. Fenavari is therefore as much a commercial packaging play as a scientific one: a branded active with a clinical backstory that manufacturers can drop into capsules, powders, drinks or multi-ingredient formulas.
For UK consumers, the comparator is still NHS-backed symptom management. The NHS says women with perimenopause or menopause symptoms should talk to a doctor, nurse or pharmacist about HRT and other options; oestrogen can be taken as tablets or used as patches, spray or gel, and vaginal oestrogen is used for vaginal dryness and irritation. The NHS also says herbal remedies and complementary medicines sold for menopause symptoms are not tested and regulated in the same way as medicines such as HRT, so safety and effectiveness are uncertain.
That is where the claim line gets sharp. Under UK rules, supplement makers cannot present food supplements as medicines or imply they treat, prevent or cure menopause symptoms. The Advertising Standards Authority has also been tightening its grip on menopause claims, which is awkward for any brand hoping to turn "clinically studied" into "clinically equivalent". Fenugreek and shatavari may well have a place in the evidence pipeline, but Fenavari still has to clear the much less glamorous hurdle of regulated language before it can claim anything close to treatment status.